Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article metrics

Inflammatory bowel disease

Original research

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Online download statistics by month:

Online download statistics by month: March 2021 to May 2023

	Abstract	Full	Pdf
Mar 2021	8581	8498	1861
Apr 2021	10938	10873	2070
May 2021	5411	5391	1275
Jun 2021	2712	2686	629
Jul 2021	1621	1599	480
Aug 2021	1713	1714	394
Sep 2021	1248	1235	350
Oct 2021	1121	1114	259
Nov 2021	808	802	235
Dec 2021	875	890	212
Jan 2022	881	915	279
Feb 2022	798	796	235
Mar 2022	987	1012	238
Apr 2022	682	672	218
May 2022	607	592	190
Jun 2022	445	448	150
Jul 2022	586	590	101
Aug 2022	322	319	102
Sep 2022	384	372	113
Oct 2022	342	329	89
Nov 2022	312	307	109
Dec 2022	274	276	78
Jan 2023	302	294	81
Feb 2023	256	259	72
Mar 2023	419	407	87
Apr 2023	525	52	28
May 2023	516	30	16
Total	43666	42472	9951